News

This award totals $65,000 to support strategic planning implementation.

The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.

Researchers in Trinity’s School of Genetics and Microbiology developed a new gene therapy, ophNdi1, that is the first of its kind to directly target mitochondrial function in cells that are malfunctioning in AMD.

Gene therapy has partly restored the function of the retina’s cone receptors in two children who were born completely colorblind, reports a new study led by UCL researchers.

Stoke Therapeutics announced enrollment of the first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy.

Sight Sciences Inc. is taking the wraps off Sion, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

According to investigators, the progression of myopia in children may be slowed by a metabolite of caffeine, known as 7-MX.

Alcon and Aerie Pharmaceuticals Inc. have announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie.

A test to detect and quantify TDP-43 deposits in the retina provides this capability for the first time and can be performed using commercially available and widely utilized diagnostic cameras.

According to researchers, functional assessments and education are critical to an early diagnosis.

In embryonic stages, tactile stimuli simultaneously activate tactile and visual neural pathways. Shortly after birth, both pathways reorganize to allow separate processing of touch and vision. The change of pathway is facilitated by the activity waves of the retina, which act as railroads that direct the stimuli of each sensory modality to the corresponding cortex, so that we can perceive them separately.

Reservoir restoration can re establish the normal anatomy and function of the conjunctiva.

By creating customized packages that incorporate the range of diagnostic and treatment options available, practices can simplify dry eye management and improve patients' outcomes.

APOE4 gene associated with Alzheimer’s disease risk was found to protect mice from glaucoma. Research team also prevented retinal ganglion cell death by blocking the APOE signaling pathway, pointing to a potential treatment strategy for glaucoma.

Oyster Point Pharma Inc. today announced that the largest Medicare pharmacy benefit manager in the United States will add its varenicline solution nasal spray (Tyrvaya) for the treatment of dry eye on its Medicare Part D formularies, effective September 1.

A team of investigators has found that myopic refractive error is linked with an increased risk of primary open-angle glaucoma, and they indicate that the connection has a genetic foundation.

According to Johns Hopkins Medicine researchers, as little as $65 per year appears to influence practitioners, making them up to twice as likely to prescribe the companies’ brand name eyedrops for glaucoma instead of cheaper generic versions.

Researchers at Linköping University have used implants made from pig skin to restore sight to 20 people with diseased corneas.

Researchers at the Medical University of Vienna are focusing on how the retina can be used as a prognostic marker. Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and the likelihood of disability.

Donald Salzberg, MD, conspired with an alleged accomplice at a medical diagnostic company in a scheme that ran for five years, from 2014 through 2019, according to U.S. attorney’s office in Boston.

The study provided evidence of safety, visual acuity improvement and structural stability in a difficult-to-treat patient population.

Anika Michael, MD, and Benjeil Edghill, MD, both ophthalmology specialists from AdvantageCare Physicians New York City, traveled to Haiti in July on a medical mission of mercy, where they evaluated and treated more than 400 patients and completed approximately 90 surgeries.

According to a news release, the U.S. Food and Drug Administration has approved Coherus’ ranibizumab-eqrn (Cimerli) as an interchangeable biosimilar for all five indications of Lucentis.

ThermaMEDx today announced a partnership with EyeCare Partners to expand EverTears distribution across the network of the national provider of clinically integrated eye care.

Combined, the companies say they will create the largest eye bank, tissue recovery and ocular research center in the world.

With the support of Harrington Discovery Institute at University Hospitals, an ophthalmic therapeutic dubbed KIO-301, initially developed by Richard Kramer, PhD, at the University of California, Berkeley (UCB), has successfully been granted approval to start a Phase 1b, first-in-human clinical trial.

Zachary Elkin, MD, MPH, of NYU Langone Eye Center, advises how ophthalmologists and parents should be aware of precautions that should be taken with sports involving small balls and urges the use of protective eyewear.